このエントリーをはてなブックマークに追加
ID 56655
JaLCDOI
フルテキストURL
著者
Okamura, Tomoka Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Washio, Yousuke Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Yoshimoto, Junko Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Tani, Kazumasa Department of Obstetrics and Gynecology, Okayama University Hospital
Tsukahara, Hirokazu Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Shimada, Akira Department of Pediatric Hematology/Oncology, Okayama University Hospital
抄録
Most cases of transient abnormal myelopoiesis (TAM) in neonates with Down syndrome (DS) resolve spontaneously; however, DS-TAM neonates with hydrops fetalis (HF) show poor clinical outcomes. We report three infants with DS-TAM and HF who were treated with exchange transfusion (ET) followed by low-dose cytarabine (LD-CA). All of them survived without developing liver failure, acute leukemia, or other serious adverse events. Our results suggest that this combination treatment with ET and LD-CA would be safe, tolerable and effective as an novel approach for DS-TAM patients with HF.
キーワード
cytarabine
Down syndrome
exchange transfusion
hydrops fetalis
transient abnormal myelopoiesis
Amo Type
Case Report
出版物タイトル
Acta Medica Okayama
発行日
2019-04
73巻
2号
出版者
Okayama University Medical School
開始ページ
181
終了ページ
188
ISSN
0386-300X
NCID
AA00508441
資料タイプ
学術雑誌論文
言語
英語
著作権者
CopyrightⒸ 2019 by Okayama University Medical School
論文のバージョン
publisher
査読
有り
PubMed ID